The Impact of Non-Alcoholic Fatty Pancreas Disease on Outcome of Acute Pancreatitis
Launched by NINGBO NO. 1 HOSPITAL · Jan 3, 2018
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
Acute pancreatitis (AP) is a common disease with a highly variable clinical course, which can range from a mild, self-limited disease to severe disease with a mortality rate of 10-20%. It is vital to distinguish severe cases early because they require more aggressive fluid resuscitation and early nutritional support.
Obesity is a well-established risk factor for acute pancreatitis (AP). It leads to ectopic fat accumulation in visceral organs, such as the liver, skeletal muscles, heart and pancreas.
Assuming that attenuation in the pancreas seen on unenhanced computed tomography (CT) scann...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. diagnosed with AP
- • 2. age\>18y
- Exclusion Criteria:
- • 1. age\<18y
- • 2. missing data in the electronic medical record
- • 3. prior attacks of AP
- • 4. without spleen
- • 5. with ambiguous pancreatic margin
About Ningbo No. 1 Hospital
Ningbo No. 1 Hospital is a leading medical institution located in Ningbo, China, dedicated to advancing healthcare through innovative clinical research and trials. With a strong emphasis on patient-centered care, the hospital is equipped with state-of-the-art facilities and a multidisciplinary team of experienced professionals. As a clinical trial sponsor, Ningbo No. 1 Hospital aims to contribute to the development of new therapies and treatment protocols, ensuring the highest standards of safety and efficacy while fostering collaboration with national and international research organizations. Their commitment to excellence in clinical research underpins their mission to enhance patient outcomes and promote medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ningbo, Zhejiang, China
Patients applied
Trial Officials
Lei Xu, Dr
Principal Investigator
Department of gastroenterology,Ningbo No.1 Hospital, Ningbo, China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials